Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.68 |
| ▸ | NADK | O95544 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.67 |
| ▸ | GNMT | Q14749 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.62 |
| ▸ | PNMT | P11086 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908433 | 0.89 | AHCY (0.72) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL6906701 | 0.89 | GNMT (0.73) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL7154290 | 0.87 | GNMT (0.73) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL6907702 | 0.86 | METTL3 (0.70) | AHCYNADKSLC29A1DOT1LDPP4 | |
| SCHEMBL6905431 | 0.86 | AHCY (0.73) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL18572550 | 0.85 | GNMT (0.76) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL6902241 | 0.85 | AHCY (0.68) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL22683279 | 0.85 | GNMT (0.76) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL18572516 | 0.85 | GNMT (0.76) | AHCYNADKSLC29A1GNMTDOT1L | |
| SCHEMBL7171951 | 0.83 | AHCY (0.66) | AHCYNADKSLC29A1GNMTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | AHCY 62/4885NADK 1514/4885SLC29A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.